Want to see NBTX full AI Analyst Report?
NBTX Stock Chart & Stats
$33.79
-$0.03(-1.02%)
At close: 4:00 PM EST
$33.79
-$0.03(-1.02%)
Day’s Range― - ―
52-Week Range$4.93 - $57.14
Previous CloseN/A
Volume23.08K
Average Volume (3M)80.27K
Market Cap
$2.02B
Enterprise Value$1.60B
Total Cash (Recent Filing)$52.75M
Total Debt (Recent Filing)$95.32M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Sep 30, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding50,619,583
10 Day Avg. Volume97,443
30 Day Avg. Volume80,267
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)-11.14
Price to Sales (P/S)31.74
P/FCF Ratio-27.70
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue54.00
Enterprise Value/Gross Profit54.00
Enterprise Value/Ebitda-132.64
Forecast
1Y Price Target
$33.00Price Target Upside-2.34% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.17
Revenue Forecast (FY)$40.51M
Bulls Say, Bears Say
Bulls Say
Intellectual Property & PlatformA broad patent estate across its nanotechnology platforms creates a durable barrier to entry, supporting exclusivity for delivery and radioenhancement approaches. This IP foundation underpins long-term licensing, partnership value and potential multi-indication extension beyond single assets.
Strategic Partnership & Regulatory MomentumAn FDA-accepted protocol amendment that shortens the event threshold can materially accelerate a pivotal readout and potential registration path. This strengthens the Janssen co-development channel and increases the likelihood of earlier milestone realization and regulatory clarity.
Extended Cash Runway / FundraisingA successful global equity raise that extends runway into 2029 materially reduces near-term refinancing risk, enabling multi-year development of Nanoprimer and ancillary platforms, supporting clinical programs and strategic partnering without immediate funding pressure.
Bears Say
Weakened Balance Sheet / LeverageNegative equity and elevated debt versus assets indicate weakened capitalization and higher leverage risk. This limits strategic flexibility, increases sensitivity to financing conditions, and raises the cost and constraints around partnering, M&A or commercialization investments.
Persistent Cash BurnConsistent negative operating and free cash flow shows the business remains cash consumptive despite revenue rebounds. Ongoing burn sustains dependence on external capital, which can dilute shareholders and force prioritization of programs rather than broad parallel development.
Early-Stage Clinical Evidence & Partner ReliancePromising signals from a seven-patient cohort are encouraging but remain preliminary; efficacy and safety must be confirmed in larger randomized studies. Heavy reliance on Janssen/MD Anderson for pivotal execution concentrates execution risk and limits Nanobiotix’s direct control over timelines.
NBTX FAQ
What was Nanobiotix Sa ADR’s price range in the past 12 months?
Nanobiotix Sa ADR lowest stock price was $4.93 and its highest was $57.14 in the past 12 months.
What is Nanobiotix Sa ADR’s market cap?
Nanobiotix Sa ADR’s market cap is $2.02B.
When is Nanobiotix Sa ADR’s upcoming earnings report date?
Nanobiotix Sa ADR’s upcoming earnings report date is Sep 30, 2026 which is in 77 days.
How were Nanobiotix Sa ADR’s earnings last quarter?
Currently, no data Available
Is Nanobiotix Sa ADR overvalued?
According to Wall Street analysts Nanobiotix Sa ADR’s price is currently Overvalued.
Does Nanobiotix Sa ADR pay dividends?
Nanobiotix Sa ADR does not currently pay dividends.
What is Nanobiotix Sa ADR’s EPS estimate?
Nanobiotix Sa ADR’s EPS estimate is -0.29.
How many shares outstanding does Nanobiotix Sa ADR have?
Nanobiotix Sa ADR has 50,619,583 shares outstanding.
What happened to Nanobiotix Sa ADR’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nanobiotix Sa ADR?
Currently, no hedge funds are holding shares in NBTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nanobiotix Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$33.00 (-2.34% Downside)
$33.00 (-2.34% Downside)
Blogger Sentiment
Bullish
NBTX Sentiment 70%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 105.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Company Description
Nanobiotix Sa ADR
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
NBTX Stock 12 Month Forecast
Average Price Target
$33.00
▼(-2.34% Downside)
Technical Analysis
―
Bicara Therapeutics Inc.
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Septerna, Inc.
―
Ownership Overview
―
Insiders
0.01% Mutual Funds
11.11% Other Institutional Investors
88.88% Public Companies and
Individual Investors